期刊文献+

标准剂量他汀类药物治疗和控油饮食对择期介入治疗术后血脂水平的影响

Effect of standard-dose statin therapy and oil-controlling diet on blood lipid levels in patients undergoing elective PCI
下载PDF
导出
摘要 目的观察择期PCI术后标准剂量他汀类药物治疗和控油饮食对血脂水平影响的效果。方法选择择期PCI的患者1 29例,按照是否实施控制油脂摄入分为控油组56例和非控油组73例,2组均给予标准剂量他汀类药物。观察术前、术后1、3和6个月血脂变化,并进行多重线性回归分析。结果与术前比较,2组术后1个月TC和LDL-C明显下降(P<0.05)。与非控油组比较,控油组患者术后1个月LDLC和TC变化值更高(P<0.05,P<0.01)。控制油脂摄入者LDL-C下降幅度大于未控油脂摄入,两组相差0.83 mmo1/L(P=0.004);女性患者较男性患者LDL-C下降明显,相差0.72 mmol/L(P=0.046)。结论择期PCI患者应用标准剂量他汀类药物治疗安全、有效,实行控油措施可进一步降低LDL-C,控油措施是血脂水平调控的重要影响因素。 Objective To observe the effect of statin therapy at standard dose and oil-controlling di et on blood lipid levels after elective pereutaneous coronary intervention(PCI). Methods 129 patients undergoing elective PCI were given standard-dose statin therapy. According to the life-style change, 56 subjects were included in the oil-controlling group whereas the rest 73 were in the non- oil-controlling group. All patients were followed up for 6 months to observe the trend of lipid change. Results Compared with the baseline,TC and LDL C had significant reduction at 1 month point (P 〈 0.05) in both groups. Oil-controlling group had significantly more reduction of TC and I.DI.-C than non oil controlling group (P 〈0.05 ,P 〈0.01). Multiple linear regression fur ther showed that LDL-C would decrease by 0.83 mmol/L more if the subjects controlled oil in- take (P -- 0. 004). Female patients got more reduction than males, however, the difference was marginal (P = 0. 046). Conclusion Standard-dose statin therapy is safe and effective for patients undergoing elective PCI and oil control will contribute to LDL C lowering.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2011年第1期33-35,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 降血脂药 药物剂量计算 膳食疗法 血脂异常 油类 急性冠状动脉综合征 antilipemic agents drug dosage calculations diet therapy dyslipidemias oils acute coronary syndrome
  • 相关文献

参考文献9

  • 1Baigent C,Keech A,Kearney PM,et al. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366:1267-1278.
  • 2Murphy SA,Cannon CP,Wiviott SD,et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes : From the PROVE IT- TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy -Thrombolysis In Myocardial Infarction 22) Trial. J Am Coll Cardiol, 2009,54 : 2358-2362.
  • 3La Rosa JC, Grundy SM, Waters DD, et al. Treating to New Targets Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005,352:1425-1435.
  • 4Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering Study group. High-dose atorvastatin versus usual- dose simvastatin for secondary prevention after myocardial infarction; the IDEAL study ; a randomized controlled trial. JAMA, 2005,294: 2437- 2445.
  • 5de Lemos JA,Blazing MA,Wiviott SD,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trial. JAMA, 2004,292 : 1307-1316.
  • 6范琰,陈亚红,刘梅林,黄樱硕,田清平,冯雪茹.老年患者应用不同类型他汀类药物的疗效及安全性评价[J].中华老年心脑血管病杂志,2010,12(1):3-5. 被引量:23
  • 7Austin PC, Mamdani MM. Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in myocardial Infarction 22/reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in Ontario,Canada. Circulation, 2005,112 : 1296- 1300.
  • 8Giraldez RR,Giugliano RP, Mohanavelu S, et al. Baseline low- density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: A PROVE IT -TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis In Myocardial Infarction 22) Analysis. J Am Coll Cardiol, 2008,52:914-920.
  • 9Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA, 2002,288 :462-467.

二级参考文献7

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5228
  • 2Lewis SJ. Statin therapy in the elderly:observational and randomized controlled trials support event reduction. Am J Geriatr Cardiol, 2004,13 : 10-16.
  • 3Ridker PM,Danielson E, Fonseca FA, et al. For the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008,359 : 2195-2207.
  • 4Grundy SM, Cleernan J I, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. Circulation, 2004, 110 : 227- 239.
  • 5Neil HA, DeMieco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study(CARDS). Diabetes Care, 2006,29 : 2378-2384.
  • 6Pedersen TR, Faergeman O, Kastelein J.l, et al. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study. J Am Med Assoc, 2005,294 : 2437-2445.
  • 7叶平.他汀类药物是抗动脉粥样硬化的基石[J].中华老年心脑血管病杂志,2009,11(6):479-480. 被引量:20

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部